Evidence map›Paper›PMID 35341739›Full record

GuidelineThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT).

Maicon Falavigna, Karlyse Claudino Belli, Alexandre Naime Barbosa, Alexandre Prehn Zavascki, Ana Catharina de Seixas Santos Nastri, Christiane Machado Santana, Cinara Stein, Débora Dalmas Gräf, Flavio Adsuara Cadegiani, Hélio Penna Guimarães and 16 more

Open access · goldAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. COVID-19 mortality in Brazil, 2020-21: consequences of the pandemic inadequate management.Archives of public health = Archives belges de sante publique · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 2 countries.

Maicon FalavignaHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil; Instituto de Avaliação de Tecnologia em Saúde (IATS), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. Electronic address: maicon@htanalyze.com.
Karlyse Claudino BelliHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
Alexandre Naime BarbosaUNESP - Faculdade de Medicina, Departamento de Infectologia, Brazil.
Alexandre Prehn ZavasckiServiço de Infectologia e Controle de Infecção do Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil; Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Serviço de Infectologia do Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
Ana Catharina de Seixas Santos NastriHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Christiane Machado SantanaUniversidade Federal da Bahia (UFBA), Bahia, Brazil.
Cinara SteinHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
Débora Dalmas GräfHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
Flavio Adsuara CadegianiCorpometria Institute, Brasília, Brazil.
Hélio Penna GuimarãesEscola Paulista de Medicina (UNIFESP-EPM), São Paulo, Brazil.
José Tadeu MonteiroUniversidade Federal do Pará, Pará, Brazil.
Juliana Carvalho FerreiraInstituto do Coração, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, São Paulo, Brazil; Hospital Sírio-Libanes, São Paulo, Brazil.
Luciano Cesar Pontes de AzevedoHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil; Hospital Sírio-Libanes, São Paulo, Brazil.
Marcelo Mihailenko Chaves MagriHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Marcone Lima SobreiraHospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB/UNESP), São Paulo, Brazil.
Maria Beatriz Gandra de Souza DiasHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil; Hospital Sírio-Libanes, São Paulo, Brazil.
Maura Salaroli de OliveiraHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil; Hospital Sírio-Libanes, São Paulo, Brazil.
Mirian de Freitas Dal Ben CorradiHospital Sírio-Libanes, São Paulo, Brazil.
Regis RosaHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
Ricardo Souza HeinzelmannDepartamento de Saúde Coletiva da Universidade Federal de Santa Maria (UFSM), Rio Grande do Sul, Brazil; Serviço de Atenção Domiciliar do Hospital Universitário de Santa Maria, Rio Grande do Sul, Brazil.
Rosemeri Maurici da SilvaUniversidade Federal de Santa Catarina (UFSC), Santa Catarina, Brazil.
Rubens Belfort JuniorHospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB/UNESP), São Paulo, Brazil.
Sergio CimermanInstituto de Infectologia Emílio Ribas, Brazil.
Verônica ColpaniHospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
Viviane Cordeiro VeigaAssociação Beneficência Portuguesa de São Paulo (BP), São Paulo, Brazil.
Carlos Roberto Ribeiro de CarvalhoHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil; Hospital Sírio-Libanes, São Paulo, Brazil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRHospital Moinhos de Vento · BRUniversidade Federal do Rio Grande do Sul · BRBeneficência Portuguesa de São Paulo · BRFundação Faculdade de Medicina · BRHospital Sírio-Libanês · BRInstituto de Infectologia Emílio Ribas · BRUniversidade Federal da Bahia · BRUniversidade Federal de Santa Catarina · BRUniversidade Federal de Santa Maria · BRUniversidade Federal de São Paulo · BRUniversidade Federal do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil.

methodsA panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method.

resultsTen technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation.

conclusionTo date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments.

Indexed as

CardiologyCommunicable DiseasesCOVID-19COVID-19 Drug TreatmentEmergency MedicineGeriatricsAzithromycinBrazilCommunity MedicineCOVID-19 SerotherapyHumansImmunization, PassiveOutpatientsVascular Surgical ProceduresAzithromycinBrazilCOVID-19COVID-19 drug treatmentGRADEGuidelineSARS-CoV-2

Identifiers

PMID35341739
PMCPMC8926872
OpenAlexW4220818539

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.